RxSight, Inc.

Good day, and thank you for standing by. Welcome to the RxSite Fourth Quarter Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you will need to press star 11 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press star 11 again. Please be advised that today's conference call is being recorded. I would now like to turn the conference over to your speaker today, Alex Hung, Investor Relations. Please go ahead.

Thank you, Operator. Presenting today are RxSight President and Chief Executive Officer Ron Kurtz and Chief Financial Officer Chelle Tunan. Earlier today, RxSight released financial results for the three months and fiscal year ended December 31, 2022. A copy of the press release is available on the company's website. Before we begin, I would like to inform you that the comments and responses to your questions during today's call reflect management's views as of today, March 6, 2023, and will include forward-looking statements and opinion statements, including predictions, estimates, plans, expectations, and other information. Actual results may differ materially from those expressed or implied as a result of certain risks and uncertainties. These risks and uncertainties are more fully described in our press release issued earlier today and in our filings with the Securities and Exchange Commission, or SEC. Our SEC filings can be found on our website or on the SEC's website. Investors are cautioned not to place undue reliance on forward-looking statements. We disclaim any obligation to update or revise these forward-looking statements. We will also discuss certain non-GAAP financial measures. Disclosures regarding these non-GAAP financial measures, including reconciliations with the most comparable GAAP measures, can be found in the press release. Please note that this conference call will be available for audio replay on our website. With that, I will turn the call over to President and CEO, Dr. Ron Kurtz.

Good afternoon and thank you for joining us. The RxSight team finished strongly in 2022 and entered 2023 with favorable trends that signal accelerating adoption of the light adjustable lens. The only premium cataract solution that enables doctors to customize patient's vision after surgery and consistently deliver superior high quality outcomes. We are working closely with an expanding number of doctors and practices to leverage the unique advantages of our technology and grow the premium cataract market through multiple mechanisms. I'll speak more about these efforts in a few minutes, but first, Shelley will review our fourth quarter and full 2022 results, discuss recent actions to further strengthen our balance sheet, and summarize our 2023 guidance.